274 related articles for article (PubMed ID: 34992627)
1. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
Zeinalzadeh E; Valerievich Yumashev A; Rahman HS; Marofi F; Shomali N; Kafil HS; Solali S; Sajjadi-Dokht M; Vakili-Samiani S; Jarahian M; Hagh MF
Front Genet; 2021; 12():703883. PubMed ID: 34992627
[TBL] [Abstract][Full Text] [Related]
2. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
3. The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.
Arora L; Kumar AP; Arfuso F; Chng WJ; Sethi G
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30217007
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibitors: finding a home in lymphoma and leukemia.
Munoz J; Dhillon N; Janku F; Watowich SS; Hong DS
Oncologist; 2014 May; 19(5):536-44. PubMed ID: 24705981
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
8. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
9. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
10. STAT3 Activation and Oncogenesis in Lymphoma.
Zhu F; Wang KB; Rui L
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861597
[TBL] [Abstract][Full Text] [Related]
11. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
12. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
[TBL] [Abstract][Full Text] [Related]
14. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.
Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF
J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.
Brachet-Botineau M; Polomski M; Neubauer HA; Juen L; Hédou D; Viaud-Massuard MC; Prié G; Gouilleux F
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963765
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the signal transducer and activator of transcription family of genes in cancer.
Shahmarvand N; Nagy A; Shahryari J; Ohgami RS
Cancer Sci; 2018 Apr; 109(4):926-933. PubMed ID: 29417693
[TBL] [Abstract][Full Text] [Related]
17. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.
Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH
Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]